Trials / Recruiting
RecruitingNCT06154837
A Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease
A Two-part Phase 1 Randomized, Double-blind, Placebo-controlled Study to Investigate Safety, Tolerability, Immunogenicity, Pharmacokinetics and Pharmacodynamics of GSK3862995B Following Single Ascending Doses in Healthy Participants and Repeat Doses in Participants With Chronic Obstructive Pulmonary Disease
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 130 (estimated)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Accepted
Summary
The primary objective of the study is to investigate the safety and tolerability of ascending doses of GSK3862995B following single dose in healthy participants and repeat doses in participants with Chronic obstructive pulmonary disease (COPD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GSK3862995B | GSK3862995B will be administered. |
| DRUG | Placebo | Placebo will be administered. |
Timeline
- Start date
- 2023-11-27
- Primary completion
- 2027-03-31
- Completion
- 2027-03-31
- First posted
- 2023-12-04
- Last updated
- 2025-07-18
Locations
32 sites across 3 countries: United States, Germany, United Kingdom
Source: ClinicalTrials.gov record NCT06154837. Inclusion in this directory is not an endorsement.